Cutaneous T cell lymphoma: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 32: | Line 32: | ||
==Treatment== | ==Treatment== | ||
[[Cutaneous T cell lymphoma medical therapy|Medical Therapy]] | [[Cutaneous T cell lymphoma surgery|Surgery]] | [[Cutaneous T cell lymphoma cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Cutaneous T cell lymphoma future or investigational therapies|Future or Investigational Therapies]] | [[Cutaneous T cell lymphoma medical therapy|Medical Therapy]] | [[Cutaneous T cell lymphoma surgery|Surgery]] | [[Cutaneous T cell lymphoma cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Cutaneous T cell lymphoma future or investigational therapies|Future or Investigational Therapies]] | ||
==Resources== | ==Resources== | ||
Revision as of 16:26, 21 December 2018
For patient information, click here
|
Cutaneous T cell lymphoma Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Synonyms and keywords: CTCL; Mycosis fungoides; Sezary syndrome; Sezary's disease; Alibert-Bazin syndrome; Granuloma fungoides
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cutaneous T cell lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging | History and Symptoms | Physical Examination | Laboratory Findings | Biopsy | CT | MRI | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Cost-Effectiveness of Therapy | Future or Investigational Therapies